Peapack Gladstone Financial Corp Buys 161,386 Shares of Pfizer Inc. $PFE

Peapack Gladstone Financial Corp grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 22.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 866,703 shares of the biopharmaceutical company’s stock after purchasing an additional 161,386 shares during the period. Peapack Gladstone Financial Corp’s holdings in Pfizer were worth $21,581,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Kepler Cheuvreux Suisse SA acquired a new position in shares of Pfizer during the third quarter worth $16,613,000. Money Concepts Capital Corp boosted its stake in Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Penn Davis Mcfarland Inc. lifted its holdings in shares of Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after purchasing an additional 1,691,773 shares during the last quarter. Finally, Pzena Investment Management LLC boosted its stake in shares of Pfizer by 0.9% during the third quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock worth $168,565,000 after buying an additional 56,484 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PFE. HSBC boosted their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Citigroup lifted their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Performance

Shares of PFE stock opened at $26.18 on Monday. The firm has a market capitalization of $149.23 billion, a P/E ratio of 19.99 and a beta of 0.34. The company’s fifty day moving average price is $26.77 and its two-hundred day moving average price is $26.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 12 month low of $23.06 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the firm earned $0.92 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.